Dr. Charuhas G. Deshpande, MD

Dr. Deshpande practices at Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania.

Dr. Deshpande's NPI, 1780838995, was assigned on November 14, 2008. Dr. Deshpande holds Pennsylvania license MD437304.

Dr. Deshpande's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr), at 3400 Spruce Street, White Bldg 1st Flr, Philadelphia, PA 19104.

Dr. Deshpande's primary practice is Good Shepherd Penn Partners - HOPD (3400 Spruce Street, White Bldg 1st Flr) in Philadelphia, Pennsylvania. Dr. Deshpande is also affiliated with Hospital of the University of Pennsylvania. The medical group on file is Penn Medicine Lancaster General Health. Dmand AI also links Dr. Deshpande to 2 more hospitals, each named with a free account. Dr. Deshpande's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Deshpande practices, 4 sites in all. Vendor and product names are available with a free account.

Anatomic pathology and clinical pathology is Dr. Deshpande's primary specialty in the NPI Registry, under taxonomy code 207ZP0102X. Dmand AI has Dr. Deshpande's licenses on file in 3 states: Pennsylvania, Illinois and New York.

CMS data shows 3,577 Medicare services from Dr. Deshpande across 13 procedure codes in 2024, for 556 Medicare patients. Medicare paid $115,323 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 556 Medicare patients who saw Dr. Deshpande in 2024. The largest group is 65 to 74, with 300 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.94, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Deshpande's median patient age at 66, with 56% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Deshpande for performance year 2024, reported individually. Dr. Deshpande accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 33 general payments to Dr. Deshpande from 3 drug and device companies from 2016 to 2019. Speaker and faculty fees make up the largest share, 76% of the total. Merck Sharp & Dohme Corporation paid the most, $20,875.